...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Rheumatology >Pamidronate in the treatment of childhood SAPHO syndrome.
【24h】

Pamidronate in the treatment of childhood SAPHO syndrome.

机译：帕米膦酸治疗儿童SAPHO综合征。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: SAPHO syndrome is increasingly recognized within the paediatric population. Conventional therapeutic approaches have often not been effective. Pamidronate is a second-generation bisphosphonate that affects bone turnover and demonstrates anti-inflammatory properties. In small case series it has given symptomatic relief to adults with this condition. OBJECTIVES: To report the clinical experience with pamidronate in childhood SAPHO syndrome. METHODS: A retrospective observational study of all children with SAPHO syndrome treated with pamidronate between 1996 and 2003 at a tertiary rheumatology centre. The standard dosing regime for pamidronate was 1 mg/kg to a maximum of 30 mg, administered daily for three consecutive days, repeated 3-monthly as required. Response to treatment was determined by clinical observation, patient subjective response and reduction in other treatments RESULTS: Seven girls were treated, with a median (range) age at diagnosis of 11 yr (9-15 yr). All patients demonstrated a beneficial clinical response, with relief of pain, increased activity and improved well-being. Subsequent courses of pamidronate were used in all patients. Other medications including corticosteroids and methotrexate could subsequently be stopped. Transient symptoms were associated with the initial course of pamidronate in some patients. No serious adverse events were reported. CONCLUSIONS: Pamidronate was associated with a marked improvement in function and well-being, and a reduction of pain and use of other medications in all patients, with no significant adverse effects. This study represents preliminary clinical data. A prospective multicentre study is necessary to assess the role and long-term safety of pamidronate in the management of childhood SAPHO syndrome
机译：背景：SAPHO综合征在儿科人群中得到越来越多的认识。常规的治疗方法常常无效。帕米膦酸盐是第二代双膦酸盐，可影响骨骼更新并具有抗炎特性。在小病例系列中，它使这种情况的成年人症状减轻。目的：报告帕米膦酸盐治疗儿童SAPHO综合征的临床经验。方法：对1996至2003年间在三级风湿病学中心接受帕米膦酸治疗的所有SAPHO综合征患儿进行回顾性观察研究。帕米膦酸的标准给药方案为1 mg / kg至最大30 mg，连续三天每天给药，根据需要每月3个月重复一次。通过临床观察，患者主观反应和其他治疗方法的减少来确定对治疗的反应结果：治疗了7名女孩，诊断时的平均年龄（范围）为11岁（9-15岁）。所有患者均表现出有益的临床反应，可减轻疼痛，增加活动量并改善健康状况。所有患者均接受随后的帕米膦酸治疗。随后可以停止使用其他药物，包括皮质类固醇和甲氨蝶呤。在某些患者中，短暂症状与帕米膦酸的初始过程有关。没有严重不良反应的报道。结论：帕米膦酸与所有患者的功能和健康显着改善，疼痛减轻和使用其他药物有关，且无明显不良反应。这项研究代表了初步的临床数据。有必要进行前瞻性多中心研究，以评估帕米膦酸在儿童SAPHO综合征管理中的作用和长期安全性

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号